Apellis Pharmaceuticals
Stock Forecast, Prediction & Price Target

Apellis Pharmaceuticals (APLS) stock Price Target by analysts

Last Year
Average Price Target

$62.8

Potential upside: 135.91%

Based on 4 analysts

Apellis Pharmaceuticals price prediction

Strike.market

What is Apellis Pharmaceuticals stock analysts` prediction?

Apellis Pharmaceuticals stock forecast: Based on 4 Wall Street analysts` predicted price targets for Apellis Pharmaceuticals in the last 3 months, the avarage price target is $62.8, with a high forecast of $NaN. The average price target represents a 135.91% change from the last price of $26.62.

Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.

Apellis Pharmaceuticals stock Price Target by analysts

Full breakdown of analysts given Apellis Pharmaceuticals price targets

Analyst name & company
Analyst win rate
Publish date
Price target
Price when posted
Source Historical targets
Douglas Tsao
H.C. Wainwright
0%
0/2
10 months ago $57 114.12% upside $27.01 StreetInsider
Previous targets (1)
Colleen Kusy
Robert W. Baird
0%
0/3
12 months ago $92 245.60% upside $31.75 StreetInsider
Previous targets (2)
Annabel Samimy
Stifel Nicolaus
50%
1/2
12 months ago $84 215.55% upside $31.68 StreetInsider
Previous targets (1)
Graig Suvannavejh
Mizuho Securities
0%
0/3
12 months ago $39 46.50% upside $36.73 StreetInsider
Previous targets (2)
Graig Suvannavejh
Mizuho Securities
0%
0/3
12 months ago $42 57.77% upside $37.62 StreetInsider
Previous targets (2)
Colleen Kusy
Robert W. Baird
0%
0/3
about 1 year ago $96 260.63% upside $37.66 TheFly
Previous targets (2)
Akash Tewari
Jefferies
0%
0/2
about 1 year ago $82 208.03% upside $37.66 StreetInsider
Previous targets (1)
Douglas Tsao
H.C. Wainwright
0%
0/2
about 1 year ago $83 211.79% upside $36 TheFly
Previous targets (1)
Colleen Kusy
Robert W. Baird
0%
0/3
about 1 year ago $86 223.06% upside $38.88 TheFly
Previous targets (2)
Graig Suvannavejh
Mizuho Securities
0%
0/3
about 1 year ago $49 84.07% upside $38.36 StreetInsider
Previous targets (2)
Derek Archila
Wells Fargo
50%
1/2
over 1 year ago $48 80.31% upside $43.6 TheFly
Previous targets (1)
Akash Tewari
Jefferies
0%
0/2
over 1 year ago $80 200.52% upside $68.16 StreetInsider
Previous targets (1)
Derek Archila
Wells Fargo
50%
1/2
over 2 years ago $58 117.88% upside $51.71 TheFly
Previous targets (1)
Unknown
J.P. Morgan
N/A
almost 3 years ago $79 196.76% upside $46.61 Benzinga
N/A
Unknown
Wedbush
N/A
almost 3 years ago $67 151.69% upside $67.07 Benzinga
N/A
Unknown
Stifel Nicolaus
N/A
almost 3 years ago $65 144.17% upside $65.38 Benzinga
N/A
Unknown
Oppenheimer
N/A
about 3 years ago $78 193.01% upside $65.5 Benzinga
N/A
Unknown
Credit Suisse
N/A
about 3 years ago $52 95.34% upside $63.58 Benzinga
N/A
Unknown
Goldman Sachs
N/A
about 3 years ago $102 283.17% upside $62.33 Benzinga
N/A
Unknown
Raymond James
N/A
about 3 years ago $113 324.49% upside $62.33 Benzinga
N/A
Unknown
Citigroup
N/A
about 3 years ago $86 223.06% upside $52.06 Benzinga
N/A
Annabel Samimy
Stifel Nicolaus
50%
1/2
about 3 years ago $60 125.39% upside $44.53 Pulse 2.0
Previous targets (1)
Matthew Luchini
BMO Capital
100%
1/1
almost 4 years ago $69 159.20% upside $37.34 TipRanks Contributor
Previous targets (0)
Laura Chico
Wedbush
100%
1/1
almost 4 years ago $28 5.18% upside $37.34 TheFly
Previous targets (0)
Alethia Young
Cantor Fitzgerald
100%
1/1
almost 4 years ago $74 177.98% upside $33.59 TheFly
Previous targets (0)
Chris Howerton
Jefferies
100%
1/1
almost 4 years ago $74 177.98% upside $33.59 TipRanks
Previous targets (0)
Tiago Fauth
Credit Suisse
100%
1/1
almost 4 years ago $38 42.74% upside $34.93 Benzinga
Previous targets (0)
Phil Nadeau
Cowen & Co.
100%
1/1
about 4 years ago $70 162.96% upside $67.8 TheFly
Previous targets (0)

Apellis Pharmaceuticals Financial Estimates

Apellis Pharmaceuticals Revenue Estimates

Apellis Pharmaceuticals EBITDA Estimates

Apellis Pharmaceuticals Earnings per Share Estimates

Passed Analyst forecast
Metric 12/31/2021 12/31/2022 12/31/2023 12/31/2025 12/31/2026 12/31/2027 12/31/2028
Revenue
 
% change YoY
$66.56M
 
N/A
$75.42M
 
13.30%
$396.59M
 
425.82%
Avg: $1.19B
Low: $1.00B
High: $1.44B
avg. 200.79%
Avg: $1.65B
Low: $1.43B
High: $2.07B
avg. 38.62%
Avg: $1.75B
Low: $1.52B
High: $2.20B
avg. 6.23%
Avg: $1.95B
Low: $1.70B
High: $2.46B
avg. 11.49%
Net Income
 
% change YoY
$-746.35M
 
N/A
$-652.17M
 
12.61%
$-528.62M
 
18.94%
Avg: $100.90M
Low: $-104.43M
High: $485.39M
avg. 119.08%
Avg: $385.45M
Low: $3.56M
High: $797.51M
avg. 281.99%
Avg: $525.38M
Low: $436.54M
High: $700.78M
avg. 36.30%
Avg: $640.46M
Low: $532.16M
High: $854.27M
avg. 21.90%
EBITDA
 
% change YoY
$-533.00M
 
N/A
$-584.5M
 
-9.66%
$-495.21M
 
15.27%
Avg: $-676.51M
Low: $-820.20M
High: $-570.01M
avg. -36.61%
Avg: $-937.78M
Low: $-1.17B
High: $-815.81M
avg. -38.62%
Avg: $-996.25M
Low: $-1.25B
High: $-866.67M
avg. -6.23%
Avg: $-1.11B
Low: $-1.39B
High: $-966.31M
avg. -11.49%
EPS
 
% change YoY
-$8.84
 
N/A
-$6.15
 
30.42%
-$4.45
 
27.64%
Avg: $0.97
Low: -$0.88
High: $4.09
avg. 121.82%
Avg: $3.19
Low: $0.03
High: $6.72
avg. 228.78%
Avg: $4.43
Low: $3.68
High: $5.9
avg. 38.62%
Avg: $5.4
Low: $4.48
High: $7.2
avg. 21.90%
Operating Expenses
 
% change YoY
$597.64M
 
N/A
$664.39M
 
11.17%
$855.20M
 
28.71%
Avg: $2.18B
Low: $1.83B
High: $2.64B
avg. 155.13%
Avg: $3.02B
Low: $2.63B
High: $3.80B
avg. 38.62%
Avg: $3.21B
Low: $2.79B
High: $4.03B
avg. 6.23%
Avg: $3.58B
Low: $3.11B
High: $4.50B
avg. 11.49%

FAQ

What is Apellis Pharmaceuticals stock earnings growth forecast?

Wall Street analysts estimate the annual average earnings growth rate of 114.82% in 2025-2028.

We have gathered data from 13 analysts. Their low estimate is -104.43M, average is 100.90M and high is 485.39M.

What is Apellis Pharmaceuticals stock revenue growth forecast?

Wall Street analysts forecast annual average revenue growth of 64.28% in 2025-2028.

We have gathered data from 13 analysts. Their low revenue estimate is $1.00B, average is $1.19B and high is $1.44B.

What is Apellis Pharmaceuticals stock earnings per share growth forecast?

Wall Street analysts forecast annual average earnings growth of 102.78% in 2025-2028.

We have gathered data from 13 analysts. Their low earnings per share estimate is -$0.88, average is $0.97 and high is $4.09.

What is the best performing analyst?

In the last twelve months 4 analysts have been covering Apellis Pharmaceuticals stock. The most successful analyst is Douglas Tsao.